Literature DB >> 12970029

Surgical treatment of superior sulcus tumors: results and prognostic factors.

Marco Alifano1, Massimiliano D'Aiuto, Pierre Magdeleinat, Eric Poupardin, Aziz Chafik, Salvatore Strano, Jean François Regnard.   

Abstract

OBJECTIVES: To study the clinical characteristics, treatment modalities, and outcome of patients with superior sulcus tumors who underwent surgery over a 15-year period.
DESIGN: Retrospective clinical study.
METHODS: Clinical records of all patients operated on for superior sulcus tumors by the same surgical team between 1988 and 2002 were reviewed retrospectively.
RESULTS: Sixty-seven patients were operated on in this period. All the patients underwent en bloc lung and chest wall resection. Surgical approaches were as follows: posterolateral thoracotomy according to Paulson (n = 33), combined transcervical and transthoracic approach (n = 33), and isolated transcervical approach (n = 1). Types of pulmonary resection included lobectomies (n = 59), pneumonectomies (n = 2), and wedge resections (n = 6). Pathologic stages were IIB, IIIA, and IIIB in 49 cases, 12 cases, and 6 cases, respectively. Resection was complete in 55 patients (82%). Operative mortality was 8.9% (n = 6). Postoperative treatment was administered in 53 patients (radiotherapy, n = 42; chemoradiotherapy, n = 9; and chemotherapy, n = 2). Overall 2-year and 5-year survival rates were 54.2% and 36.2%, respectively. Five-year survival was significantly higher after complete resection than after incomplete resection (44.9% vs 0%, p = 0.000065). The presence of associated major illness negatively affected the outcome (5-year survival, 16.9% vs 52%; p = 0.043). Age, weight loss, respiratory impairment, tumor size, presence of nodal disease, and histologic type did not influence the long-term outcome. At multivariate analysis, only the completeness of resection and the absence of associated major comorbidities had an independent positive prognostic value.
CONCLUSIONS: Superior sulcus tumor remains an extremely severe condition, but long-term survivals may be achieved in a large percentage of cases. The presence of associated major illness and the completeness of resection are the two most important factors affecting the long-term outcome.

Entities:  

Mesh:

Year:  2003        PMID: 12970029     DOI: 10.1378/chest.124.3.996

Source DB:  PubMed          Journal:  Chest        ISSN: 0012-3692            Impact factor:   9.410


  7 in total

1.  Pancoast's tumour presenting as shoulder pain in an orthopaedic clinic.

Authors:  Lynne Ronan; Sunil D'Souza
Journal:  BMJ Case Rep       Date:  2013-02-05

Review 2.  Treatment of pancoast tumors from the surgeons prospective: re-appraisal of the anterior-manubrial sternal approach.

Authors:  Haralabos Parissis; Vincent Young
Journal:  J Cardiothorac Surg       Date:  2010-11-04       Impact factor: 1.637

3.  Analysis of the surgical treatment for superior sulcus tumors.

Authors:  Yoshinobu Ichiki; Akira Nagashima; Manabu Yasuda; Mitsuhiro Takenoyama
Journal:  Surg Today       Date:  2012-12-02       Impact factor: 2.549

Review 4.  Superior sulcus (Pancoast) tumors: current evidence on diagnosis and radical treatment.

Authors:  Christophoros N Foroulis; Paul Zarogoulidis; Kaid Darwiche; Nikolaos Katsikogiannis; Nikolaos Machairiotis; Ilias Karapantzos; Kosmas Tsakiridis; Haidong Huang; Konstantinos Zarogoulidis
Journal:  J Thorac Dis       Date:  2013-09       Impact factor: 2.895

Review 5.  Superior sulcus tumors (Pancoast tumors).

Authors:  Giuseppe Marulli; Lucia Battistella; Marco Mammana; Francesca Calabrese; Federico Rea
Journal:  Ann Transl Med       Date:  2016-06

6.  Three-stage approach to resection of left pancoast tumour with spinal and major vessel involvement.

Authors:  Alison M Wallace; George D Oreopoulos; Yoga R Rampersaud; Thomas K Waddell
Journal:  J Surg Case Rep       Date:  2020-12-14

7.  The Favorable Prognostic Factors for Superior Sulcus Tumor: A Systematic Review and Meta-Analysis.

Authors:  Xiaohu Hao; Zihuai Wang; Diou Cheng; Jian Zhou; Nan Chen; Qiang Pu; Lunxu Liu
Journal:  Front Oncol       Date:  2020-10-20       Impact factor: 6.244

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.